The office has had an exciting time over the last season; lots of visitors, presentations and symposiums. Technology Transfer & Intellectual Property Services (TTIPS) welcomed visitors from Japan, China, Taiwan, Germany, the US State Department, and other state and private universities. Many of these visitors wanted to learn about the University’s role in transferring innovations into the public sector and to understand the success of UCSD endeavors in the local San Diego region. Recent changes abroad, mirroring the US Bayh-Dole Act, have prompted these international countries to study the US system of university technology transfer practices, and UCSD in particular.

Events recently sponsored by TTIPS includes the Oncology Partnership Forum, AgBio Symposium, Invention Review meetings/LEAP presentations, and individual educational programs to departments including an university class on intellectual Property at UCSD Extension.

Our staff attended and represented UCSD at Bio2001, AUTM 2002, AUTM Chapter meetings, LES National Meeting, UC System Patent Coordinators Meetings, and various other affiliated symposiums. Dr. Alan Paau, our Director, traveled to Brazil to present to the World Intellectual Property Organization. In January he traveled to Japan at the request of Meijo University to speak on the management and marketing of intellectual property in universities.

Editor—Alexa Falkenstein

DuPont has donated intellectual property, including patents, trademarks, and technical information to the University of California, San Diego. The agreement, brokered by TTIPS, states the university’s engineering faculty will continue to develop the intellectual property for applications ranging from flat-panel displays to pollution abatement.

The donation includes 11 patents issued or filed pertaining to the trademarked Tacky Dot® technology. DuPont scientists developed Tacky Dot® as a way to mount both rapidly and precisely particles on surfaces. So-called tacky, or adhesive, dots, comprised of photopolymer materials, are created in precise patterns, so the mounting process of single particles can be as simple as dusting the sample onto the surface saving valuable time and materials in, for example, solder bump-
The technology has many potential applications in the electronics industry, but specific examples being developed at UCSD include the mounting many particles on a tacky area and the use of Tacky Dot® with phosphors and photocatalytic materials.

Since the applications fall outside of the company's core product strategy, DuPont agreed to donate all Tacky Dot® rights to UCSD. With this new opportunity, UCSD plans to:
- actively develop the technology for two applications (displays and photocatalysis);
- make a good-faith effort to license parts of the technology to third parties; and
- continue to prosecute the five patent applications already filed, and four others under consideration for filing.

The Tacky Dot® research at UCSD will take place in the Jacobs School laboratory of Dr. Jan Talbot, professor of chemical engineering at UCSD. "Our research will focus on using the adhesive dots and covering them with small-diameter powders," said Talbot, "Luminescent phosphor powder will be tested to improve the image quality of flat-panel display screens, while powder made of photocatalytic materials will be used in experiments on panels that harness solar rays to produce energy, clean up waste water, or mitigate air pollution."

DuPont's Director of Business/Technology Licensing, Dr. Jay Rappaport, said that the University of California, San Diego, was selected for this donation because of the University's unique strengths and capabilities in the areas where the Tacky Dot® Technology has greatest market potential, the faculty's demonstrated ability to enhance educational opportunities through the use of new technology, and the University Technology Transfer and IP Services’s proven track record in capitalizing on intellectual property to generate revenue and create startup companies for the benefit of the University.

AirFiber was founded in May 1998 with technology developed by UCSD Professor Anthony Acampora and licensed via UCSD's Technology Transfer and Intellectual Property Services (TTIPS) Office. Since then, AirFiber has endeavored to deliver scalable and affordable broadband service to the "last mile" of telecommunication networks. Their OptiMesh technology provides 622 Mbps transmission rates over a wireless optical network, extending high-bandwidth capacity to buildings not yet connected to a fiber optic backbone. The low cost quick installation of the OptiMesh system allows new buildings to be brought on-net within days,
at a fraction the cost of running new fiber connections. This low cost solution is changing the “sell then build” paradigm of telecommunications carriers, allowing instead a “build then sell” business model. New customers can be brought on-net within days of their initial request. OptiMesh provides 99.999% availability through the use of a mesh configuration, giving multiple paths and automatic rerouting in case of interference or equipment malfunction.

Learn more about AirFiber at www.airfiber.com or call (858)676-7000.

UCSD START-UP COMPANY CONTINUES CLINICAL STUDIES

On February 4, 2002 Neoprobe Corporation announced that it has completed an exclusive license agreement with the University of California, San Diego (UCSD). The license affords Neoprobe the rights to a proprietary compound developed by researchers at UCSD. The compound, which Neoprobe has designated Lymphoseek(TM), is being evaluated in clinical studies to determine its effectiveness in identifying lymphatic tissue in breast and in melanoma cancer patients.

David Bupp, Neoprobe’s president and CEO, said, “We are very pleased to have licensed Lymphoseek from UCSD. The initial clinical results from the Phase I clinical studies encouraged us to accelerate the Lymphoseek licensing activities. The technology transfer was accomplished in a very effective and timely manner. We will be working with the Phase I researchers to complete a submission package to the United States FDA to seek permission to begin the next phase of Lymphoseek clinical evaluation.”

David Vera, MD of the Radiology Department and the inventor of the compound, said “Based on my previous experience in the early ’80s with the U.C. Patent Board, I was extremely impressed with the expertise and organization of the Technology Transfer and Intellectual Property Services office.”

Neoprobe has since announced it has reached its second year of profitability.

Dr. Vera is continuing early phase clinical studies, and is in the planning stages for additional clinical trials.

"... I was extremely impressed with the expertise and organization of the Technology Transfer and Intellectual Property Services office."

NEW LOCAL START-UP BASED UPON CUTTING-EDGE UCSD BIOLOGICAL TECHNOLOGY

The TTIPS office has just executed a license for the use of new medical software with a San Diego start-up company, Insilicomed, Incorporated. The tools were developed by a research team led by Professor Andrew McCulloch and Professor Jeffrey Omens in the Department of Bioengineering at UCSD. Insilicomed (www.insilicomed.com), located in La Jolla, is a new start-up biomedical software company that will provide a broad range of computer applications and services for the biotechnology and biomedical device industries. These include innovative predictive modeling software for medical device engineering, diagnostic imaging, and surgical planning. Currently, Insili-
comed is using the application for its contract with Paracor Surgical, Incorporated, to model a novel device for the treatment of patients with congestive heart failure. UCSD is presently negotiating an exclusive license with Insilicomed that will allow it to customize and sell biomedical software to its clients. This additional capability will allow Insilicomed to expand rapidly from a company with 3 employees to one of a dozen or more within the next two years.

As always, UCSD will welcome interest from investors seeking a sound opportunity for substantial returns. Please contact Dr. Laura Wolszon in the TTIPS office at (858) 534-7017 with questions.

For information about the services provided by Insilicomed, contact Dr. Lewis Waldman at (858) 459-4192 or info@insilicomed.com.

DO YOU KNOW...

... that any mice purchased from Jackson Labs cannot be bred or transferred to anyone without permission.

SELECTED RECENTLY ISSUED PATENTS

Novel Interleukin-1 and TNF-Alpha Modulators Synthesis of Said Modulators and Methods of Using Said Modulators (US Patent No. 6,365,768)

- Dr. Emmanuel Theodorakis (Chem/BioChem)

Prevention of Liver Fibrosis by Inhibition of Stellate Cell Activation (US Patent No. 5,922,757)

- Dr. Mario Chojkier (Medicine)

Development of Metallic/Intermetallic Materials for Lightweight Armor (US Patent No. 6,357,332)

- Dr. Kenneth Vecchio (Engineering)

SELECTED RECENTLY LICENSED INVENTIONS

Control of Immune Responses by Modulating Activity of Glycosyltransferases

- Dr. Jamey Marth (Cell. & Mol. Med.)

ST6GAL-1 Deficient Mice

- Dr. Jamey Marth (Cell. & Mol. Med.)

Cloned Human Type II Sodium Channel cDNA

- Dr. Mauricio Montal (Biology)

Anti-Light Hybridoma Cell Line

- Dr. Thomas Kipps (Medicine)

Macromolecular Carrier for Drug and Diagnostic Agent Delivery

- Dr. David Vera (Radiology)

Methods of Epitope-Specific and Cytokine/Anti-Cytokine ImmunoTherapy for Modulation of Pathogenic Immune Responses in Mediated Diseases

- Dr. Salvatore Albani (Pediatrics)